| Aug 9 |
India Globalization Capital GAAP EPS of -$0.03 in-line, revenue of $0.27M misses by $0.04M
|
| Aug 9 |
IGC Pharma Reports First Quarter Fiscal 2025 Results
|
| Jul 18 |
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
|
| Jul 9 |
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
|
| Jun 25 |
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
|
| Jun 25 |
IGC Pharma GAAP EPS of -$0.22 in-line, revenue of $1.35M beats by $0.11M
|
| Jun 24 |
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
|
| Jun 18 |
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
|
| Jun 10 |
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
|
| May 28 |
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
|
